Lysis Biotech is dedicated in making available for the Greek patients in need a breakthrough therapy for Peripheral T-cell lymphoma (PTCL).
Lysis Biotech is dedicated in making available for the Greek patients in need a breakthrough therapy for Peripheral T-cell lymphoma (PTCL). Lysis ensures access by navigating through the particularities of the Greek Healthcare environment serving a high unmet need area.
Peripheral T-cell lymphoma (PTCL) is defined as a diverse group of aggressive lymphomas that develop from mature-stage white blood cells called T-cells and natural killer (NK) cells. It is PTCL’s origin in the lymphatic system that gave it the name peripheral T-cell lymphoma. In the case of PTCL, the term “peripheral” does not refer to the extremities, but identifies PTCL as a cancer that arises in the lymphoid tissues outside of the bone marrow such as lymph nodes, spleen, gastrointestinal tract, and skin.
PTCLs are aggressive (fast-growing) lymphomas, and include PTCL-not otherwise specified (NOS), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), enteropathy-associated T-cell lymphoma (EATL), and extranodal natural killer (NK)/T-cell lymphoma (ENKTL). The incidence of PTCL subtypes varies geographically.